Upcoming Series

Tecovirimat shows no significant effect on the duration of mpox lesions in a study conducted in the Democratic Republic of the Congo

The antiviral drug tecovirimat did not reduce the duration of mpox lesions in children and adults with the Impox clade in the Democratic Republic of the Congo (DRC), according to an initial investigation of data from a randomized placebo-controlled trial.

Tecovirimat shows no significant effect on the duration of mpox lesions in a study conducted in the Democratic Republic of the Congo Read More »